Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Randomised, Clinical Phase II Trial in Patients With Unresectable Advanced Pancreatic Cancer Investigating the Efficacy, Safety, and Pharmacokinetics of BI 2536 Administered in Repeated 3-week Cycles as a Single i.v. Dose of 200 mg on Day 1 or as 60 mg Doses on Days 1, 2, and 3

NCT00710710 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00710710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00710710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Randomised, Clinical Phase II Trial in Patients With Unresectable Advanced Pancreatic Cancer Investigating the Efficacy, Safety, and Pharmacokinetics of BI 2536 Administered in Repeated 3-week Cycles as a Single i.v. Dose of 200 mg on Day 1 or as 60 mg Doses on Days 1, 2, and 3
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2006
Completion date
October 14, 2008
Enrollment
89 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasms